Commentary

TikTok’s fave weight loss drugs: Link to thyroid cancer?


 

How to advise our patients and respond to the EMR messages

The TikTok videos may continue, the celebrity chatter may increase, and we, as physicians, will continue to look to real-world data with randomized controlled trials to tailor our decision-making and guide our patients.

It’s prudent to advise patients that if they have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, in particular, they should avoid using this class of medication. Thyroid cancer remains a rare outcome, and GLP-1 receptor agonists remain a very important and beneficial treatment option for the right patient.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Hypothyroidism: No more waiting to eat or drink with liquid thyroxine?
Federal Practitioner
Hyperthyroidism rebound in pregnancy boosts adverse outcomes
Federal Practitioner
Thyroid autoimmunity linked to cancer, but screening not advised
Federal Practitioner
Don’t be afraid of weight gain with hyperthyroid treatment
Federal Practitioner
Stopping levothyroxine in subclinical hypothyroidism safe, feasible
Federal Practitioner
USPSTF holds firm on postmenopausal hormone recommendations
Federal Practitioner
Thyroid nodule volume reduction correlates with energy in ablation
Federal Practitioner
Lifestyle choices could curb genetic risk for thyroid cancer
Federal Practitioner
Taking a break from TKIs unlikely to shorten survival
Federal Practitioner
What’s it like to take Ozempic? A doctor’s own story
Federal Practitioner